Shares of the pharma company ended 1.3% lower at ₹1,442.00 on Tuesday. Previous Post Suzlon receives advisory warning from NSE and BSE for non-compliance with SEBI regulations Next Post Swiggy provides special indemnities to directors of SoftBank, Accel and Prosus, ahead of IPO Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
